Gates Foundation Strategic Investment Fund Logo


Kymab has developed a proprietary mouse platform which contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.

Just Biotherapeutics

Just Biotherapeutics is developing an integrated technology platform to accelerate the development and manufacturing of high-quality biologics at a significantly lower cost, to broaden global biologic access.

Press Release: Kymab secures US $100 million Series C funding

Kymab November 24, 2016 Kymab Group Limited (“Kymab”), a leading monoclonal antibody biopharmaceutical group, announced today that it has successfully secured a US$100 million (£81 million) Series C financing. The financing was led by new investors ORI Healthcare Fund L.P. Read More